Skip to main content

Advertisement

SpringerLink
Log in

Excipient-Induced Pulmonary Vascular Disease: An Underrecognized and Deadly Complication of Opioid Addiction

  • PULMONARY VASCULAR DISEASE
  • Published:
Lung Aims and scope Submit manuscript

Abstract

Despite widespread public health concern regarding opioid misuse and overuse, there is a paucity of literature on the acute and chronic pulmonary vascular and cardiac implications of excipient lung disease. This case series describes the clinical presentation of five adult patients who experienced profound pulmonary hypertension and right heart failure in the setting of confirmed or suspected crushed opioid injection at a single academic center between 2012 and 2019. The clinical characteristics and right heart catheterization data presented in these cases demonstrate the acute intravascular effects of the intravenous injection of crushed opioids and potential for hemodynamic collapse. Moreover, these cases suggest that survivors of acute excipient lung disease may develop chronic pulmonary vascular disease. Further studies are needed to explore the epidemiology and outcomes of oral opioid-induced intravascular excipient lung disease to increase awareness of this life-threatening complication among health care professionals and guide treatment and prevention measures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. U.S. Department of Health and Human Services (2017) HHS acting secretary declares public health emergency to address national opioid crisis. U.S. Department of Health and Human Services, Washington, DC

    Google Scholar 

  2. The opioid epidemic by the numbers (2019) http://hhs.gov/opioids/sites/default/files/2019-11/Opioids%20Infographic_letterSizePDF_10-02-19.pdf. Accessed 19 Nov 2019

  3. Nguyen VT, Chan ES, Chou SS et al (2014) Pulmonary effects of IV injection of crushed opioid tablets: “excipient lung disease.” AJR Am J Roentgenol 203(5):W506–W515

    Article  Google Scholar 

  4. Sigdel S, Gemind JT, Tomashefski JF (2011) The Movat pentachrome stain as a means of identifying microcrystalline cellulose among other particulates found in lung tissue. Arch Pathol Lab Med 135(2):249–254

    Article  Google Scholar 

  5. Ganesan S, Felo J, Saldana M, Kalasinsky VF, Lewin-Smith MR, Tomashefski JF Jr (2003) Embolized crospovidone (poly[N-vinyl-2-pyrrolidone]) in the lungs of intravenous drug users. Mod Pathol 16:286–292

    Article  Google Scholar 

  6. Tomashefski JF, Felo JA (2004) The pulmonary pathology of illicit drug and substance abuse. Curr Diagn Pathol 10:413–426

    Article  Google Scholar 

  7. Excipients browser. http://excipients.ucsf.bkslab.org/index. Accessed 21 Jan 2019

  8. Arnett EN, Battle WE, Russo JV, Roberts WC (1976) Intravenous injection of talc-containing drugs intended for oral use: a cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med 60(5):711–718

    Article  CAS  Google Scholar 

  9. Griffith CC, Raval JS, Nichols L (2012) Intravascular talcosis due to intravenous drug use is an underrecognized cause of pulmonary hypertension. Pulm Med 2012:617531–617531

    Article  Google Scholar 

  10. Yakel DL Jr, Eisenberg MJ (1995) Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J 130(2):398–399

    Article  Google Scholar 

  11. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53(1):1801913

    Article  CAS  Google Scholar 

  12. Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, Kudelko K, Liu J, Hsi A, Rupp A, Sweatt AJ, Tuder R, Berry GJ, Rabinovitch M, Doyle RL, de Jesus PV, Kawut SM (2018) Features and outcomes of methamphetamine-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 197(6):788–800

    Article  CAS  Google Scholar 

Download references

Funding

This research was not funded.

Author information

Authors and Affiliations

  1. Division of Pulmonary, Critical Care, & Sleep Medicine, University of Kansas School of Medicine, 3901 Rainbow Boulevard, Mail Stop #3007, Kansas City, KS, 66160-7381, USA

    Christine M. Cook, Steven Q. Simpson & Lewis Satterwhite

Authors
  1. Christine M. Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven Q. Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lewis Satterwhite
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Authors contributed equally.

Corresponding author

Correspondence to Lewis Satterwhite.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cook, C.M., Simpson, S.Q. & Satterwhite, L. Excipient-Induced Pulmonary Vascular Disease: An Underrecognized and Deadly Complication of Opioid Addiction. Lung 199, 363–368 (2021). https://doi.org/10.1007/s00408-021-00456-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-021-00456-4

Keywords

Search

Navigation